Sarah Goldberg, MD, MPH, assistant professor of Medicine and Medical Oncology, Yale Cancer Center, discusses coming trials looking at immunotherapy beyond the second-line setting in non-small cell lung cancer (NSCLC).
Sarah Goldberg, MD, MPH, assistant professor of Medicine and Medical Oncology, Yale Cancer Center, discusses coming trials looking at immunotherapy beyond the second-line setting in non-small cell lung cancer (NSCLC). Goldberg says the most exciting part about these trial is finding out if combination immunotherapy treatment regimens could work better than single-agent regimens.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More